Aclaris meldet Zahlen für Q2/19
- Umsätze 6 Mio. $
- Verlust 50 Mio. $ (davon 19 Mio. $ Goodwill-Abschreibungen)
- Cash 116 Mio. $
- Cash-Reichweite ~ 3 Quartale
- MK 34 Mio. $
- neues 52 Wochen-Tief
Business Strategy Update:
- Aclaris announced that it is undertaking a strategic business review of its commercial and research and development (R&D) portfolio of assets to determine how to optimally deploy capital to maximize shareholder return. As part of this undertaking, Aclaris today announced the following:
- Today, it is voluntarily discontinuing the commercialization of ESKATA® (hydrogen peroxide) Topical Solution, 40% (w/w) (ESKATA) in the United States due to the fact that revenues from product sales were insufficient for Aclaris to sustain continued commercialization as a result of the product not achieving sufficient market acceptance by physicians and patients, and not for efficacy or safety reasons, and is seeking a strategic partner to commercialize this product, both in the United States and worldwide (excluding Canada).
- Aclaris currently intends to seek a strategic partner to further develop its investigational compounds, ATI-501 (oral) and ATI-502 (topical) Janus Kinase (JAK) 1/3 inhibitors, for alopecia.
- Aclaris plans to continue to invest in its other immuno-inflammatory drug candidates, including its internally developed investigational candidate ATI-450, an oral MK2 inhibitor. If Aclaris successfully completes its ongoing Phase 1 clinical trial for this drug candidate, Aclaris expects to advance ATI-450 into two Phase 2 clinical trials: one for patients with rheumatoid arthritis (RA) and one for an additional inflammatory indication.
http://investor.aclaristx.com/news-releases/...quarter-2019-financial
|
